» Articles » PMID: 20007507

A Novel Human Heparanase Splice Variant, T5, Endowed with Protumorigenic Characteristics

Overview
Journal FASEB J
Specialties Biology
Physiology
Date 2009 Dec 17
PMID 20007507
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Heparanase is a mammalian endo-beta-d-glucuronidase that can cleave heparan sulfate side chains, an activity strongly implicated in tumor cell dissemination. The current study aimed to identify and characterize heparanase splice variants. LEADS, Compugen's alternative splicing modeling platform (Compugen, Tel Aviv, Israel), was used to search for splice variants in silico; tumor-derived cell lines (i.e., CAG myeloma) and tumor biopsies were utilized to validate T5 expression in vivo; signaling (i.e., Src phosphorylation) was evaluated following T5 gene silencing or overexpression and correlated with cell proliferation, colony formation, and tumor xenograft development. A novel spliced form of human heparanase, termed T5, was identified. In this splice variant, 144 bp of intron 5 are joined with exon 4, which results in a truncated, enzymatically inactive protein. T5 overexpression resulted in increased cell proliferation and larger colonies in soft agar, mediated by Src activation. Furthermore, T5 overexpression markedly enhanced tumor xenograft development. T5 expression is up-regulated in 75% of human renal cell carcinoma biopsies examined, which suggests that this splice variant is clinically relevant. Controls included cells overexpressing wild-type heparanase or an empty plasmid and normal-looking tissue adjacent the carcinoma lesion. T5 is a novel functional splice variant of human heparanase endowed with protumorigenic characteristics.-Barash, U., Cohen-Kaplan, V., Arvatz, G., Gingis-Velitski, S., Levy-Adam, F., Nativ, O., Shemesh, R., Ayalon-Sofer, M., Ilan, N., Vlodavsky, I. A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics.

Citing Articles

Heparanase-A single protein with multiple enzymatic and nonenzymatic functions.

Vlodavsky I, Kayal Y, Hilwi M, Soboh S, Sanderson R, Ilan N Proteoglycan Res. 2023; 1(3):e6.

PMID: 37547889 PMC: 10398610. DOI: 10.1002/pgr2.6.


Heparanase in cancer progression: Structure, substrate recognition and therapeutic potential.

Yuan F, Yang Y, Zhou H, Quan J, Liu C, Wang Y Front Chem. 2022; 10:926353.

PMID: 36157032 PMC: 9500389. DOI: 10.3389/fchem.2022.926353.


Non-enzymatic heparanase enhances gastric tumor proliferation via TFEB-dependent autophagy.

Yang M, Tang B, Wang S, Tang L, Wen D, Vlodavsky I Oncogenesis. 2022; 11(1):49.

PMID: 35970822 PMC: 9378687. DOI: 10.1038/s41389-022-00424-4.


Glycosaminoglycans: Carriers and Targets for Tailored Anti-Cancer Therapy.

Berdiaki A, Neagu M, Giatagana E, Kuskov A, Tsatsakis A, N Tzanakakis G Biomolecules. 2021; 11(3).

PMID: 33800172 PMC: 8001210. DOI: 10.3390/biom11030395.


Heparan Sulfate Glycosaminoglycans: (Un)Expected Allies in Cancer Clinical Management.

Faria-Ramos I, Pocas J, Marques C, Santos-Antunes J, Macedo G, Reis C Biomolecules. 2021; 11(2).

PMID: 33494442 PMC: 7911160. DOI: 10.3390/biom11020136.


References
1.
Doviner V, Maly B, Kaplan V, Gingis-Velitski S, Ilan N, Vlodavsky I . Spatial and temporal heparanase expression in colon mucosa throughout the adenoma-carcinoma sequence. Mod Pathol. 2006; 19(6):878-88. DOI: 10.1038/modpathol.3800603. View

2.
Fairweather J, Hammond E, Johnstone K, Ferro V . Synthesis and heparanase inhibitory activity of sulfated mannooligosaccharides related to the antiangiogenic agent PI-88. Bioorg Med Chem. 2007; 16(2):699-709. DOI: 10.1016/j.bmc.2007.10.044. View

3.
Parish C, Freeman C, Hulett M . Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta. 2001; 1471(3):M99-108. DOI: 10.1016/s0304-419x(01)00017-8. View

4.
van Alphen R, Wiemer E, Burger H, Eskens F . The spliceosome as target for anticancer treatment. Br J Cancer. 2008; 100(2):228-32. PMC: 2634708. DOI: 10.1038/sj.bjc.6604801. View

5.
Elkin M, Ilan N, Friedmann Y, Papo O, PECKER I, Vlodavsky I . Heparanase as mediator of angiogenesis: mode of action. FASEB J. 2001; 15(9):1661-3. DOI: 10.1096/fj.00-0895fje. View